Background. In patients with end-stage renal disease, peripheral vascular disease (PVD) is prevalent. We assessed the extent to which severity of PVD predicts mortality, hospitalizations and health-related quality of life (HRQOL) in hemodialysis (HD) patients enrolled in the Hemodialysis (HEMO) Study. Methods. We performed a subanalysis of the HEMO Study, a randomized controlled trial. Adjusted predictors of PVD were analyzed through a multivariable stepwise ordinal logistic model. Relationships between PVD severity and mortality and hospitalizations were determined with Cox proportional hazards models. Relationships between PVD severity and HRQOL were modeled via linear regression and generalized estimating equations. Results. Older age, diabetes, non-African-American race, ischemic heart disease, cerebrovascular disease and longer transplant wait time were associated with more severe PVD. Patients with severe PVD were more likely to suffer from all-cause mortality [hazard ratio (HR) 1.77, 95% confidence interval 1.30-2.40, P < 0.001], cardiac death [HR 1.89 (95% confidence interval 1.15-3.11), P = 0.001] and infectious death [HR 1.75 (95% confidence interval 1.30-2.34), P < 0.001]. Increasing PVD severity was also associated with first cardiac hospitalization or all-cause mortality (P = 0.05) and first cardiac hospitalization or cardiac death (P = 0.03). HRQOL scores were lower for patients with increasingly severe PVD. Conclusions. These findings underscore the burden of clinically symptomatic PVD in HD patients and its impact on morbidity and mortality. Whether early detection of PVD and prompt initiation of therapy to prevent its progression in the HD population would improve HRQOL and survival outcomes remain to be proven.
Introduction
In patients with end-stage renal disease (ESRD), the prevalence of peripheral vascular disease (PVD) is estimated to be 17-48%, with the wide range of the prevalence likely a result of the differences in diagnostic methods and the population studied [1, 2] . In addition to the higher prevalence, PVD in patients with ESRD is more challenging to treat due to its faster progression, greater involvement of distal vessels and heavier calcification of the arteries [3] . Although risk factors for PVD diagnosis in patients with ESRD have been described by several recent major clinical studies, there has not been a study exploring the risk factors associated with PVD severity or comparing the impact of different PVD severities on survival rates and health-related quality of life (HRQOL) in patients with ESRD [4] [5] [6] [7] .
Mounting evidence suggests a complex relationship between kidney disease and PVD as patients with both conditions suffer greater mortality and respond less favorably to PVD-related interventions [6, [8] [9] [10] . The Dialysis Outcomes and Practice Patterns Study (DOPPS), an international prospective observational study of 29 873 ESRD hemodialysis (HD) patients, found that those with PVD were at increased risk for all-cause hospitalization, allcause mortality and cardiac mortality [6] . This study also showed mortality rates of ESRD patients with PVD to be higher than those without PVD despite statin and/or aspirin use [6] . Current guidelines recommend the screening of patients for PVD upon initiation of dialysis, yet optimal treatment for PVD in patients with ESRD remains undetermined [11] . To highlight some of the controversies, a recent analysis of incident-dialysis patients enrolled in the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) study reported that those who underwent PVD-related procedures (revascularization, amputation) suffered higher rates of cardiovascular events, infectious hospitalizations, PVD-related death and all-cause death compared to those who did not undergo PVD-related procedures [12] . However, a separate study comparing revascularization, amputation and no intervention concluded that those who underwent revascularization had the lowest mortality [13] . Moreover, a significant proportion of ESRD patients had limbs amputated without first attempting revascularization surgery, largely out of concern that ESRD patients undergoing revascularization surgery would experience longer hospitalization times, higher amputation rates and increased mortality [5, 11] . In searching for the most appropriate treatment for PVD, a more thorough examination of the impact of PVD in ESRD patients is warranted.
The Hemodialysis (HEMO) Study, a large-scale prospective clinical trial, provides a unique opportunity to examine the impact of PVD severity in patients with ESRD receiving maintenance HD. An analysis of the first 1000 subjects enrolled in the HEMO Study found 23% of the subjects to have PVD and that PVD was independently associated with older age, non-African-American race, diabetes and smoking [4] . We hope to further the understanding of PVD in patients with ESRD by examining factors associated with increasing PVD severity and the impact of PVD severity on mortality and quality of life. Using the data from the entire HEMO Study, we characterized the distribution of HD patients by PVD severity, identified risk factors related to PVD severity, elicited adjusted predictors of PVD severity, examined the impact of PVD severity on mortality and described the association between PVD severity and HRQOL in HD patients.
Materials and methods

Subjects
The HEMO Study was a randomized clinical trial of 1846 chronic HD patients at 15 clinical centers comprising 72 dialysis units. It was designed to study the effects of HD dose and membrane flux on mortality and morbidity in patients undergoing chronic dialysis [14] . Patients were randomized to either standard or high dose (equilibrated Kt/V of 1.05 versus 1.45, respectively) and to either high or low flux membranes (beta-2 microglobulin clearance of <10 mL/min or >20 mL/min, respectively). Patient eligibility criteria have been described previously [14] . Patients with New York Heart Association (NYHA) Class IV symptoms despite medical therapy were excluded. The patient population was followed longitudinally with scheduled maximum follow-up duration of 0.9-6.6 years and mean actual follow-up of 2.84 ± 1.84 years [15] . The primary end point was all-cause mortality. The Institutional Review Boards (IRBs) at the 15 institutions approved the study protocol and written informed consent was obtained from all study participants. Enrollment began in March 1995 and ended in October 2000. The present secondary analyses were approved by the University of Pittsburgh IRB.
Peripheral vascular disease severity
Comorbidity was assessed at baseline using the 'Index of Coexistent Disease (ICED)' based on chart review. Categories of the data reviewed include discharge summaries from hospitalization, medication record, monthly progress notes by physician, chest X-ray, electrocardiogram, echocardiogram, physician's history and physical examinations and problem list. The ICED score was determined by condensing the two index grades from the 'Index of Disease Severity (IDS)' and the 'Index of Physical Impairment' or Functional Severity and categorized into four levels, with higher numbers indicating more severe disease and/or functional impairment. Comorbid conditions were divided into 19 disease categories defined by specific clinical criteria, of which the category 'PVD' score was used to assess severity of PVD in the present study.
As part of the baseline assessment, existing or history of PVD was collected using the IDS. Each patient was given a PVD severity score of 0, 1, 2 or 3, with the details of IDS criteria listed below: PVD = 0: no peripheral vascular disease. PVD = 1: having a diagnosis of PVD or diagnosis of abdominal or thoracic aneurysm. PVD = 2: having intermittent claudication, gangrenous toes, having amputation of toes or foot, status post bypass graft, abdominal aortic aneurysm or thoracic aortic aneurysm repair. PVD = 3: experiencing pain at rest due to PVD, having PVD that is inoperable and having amputation below or above the knee.
The above scoring definitions were modified from the IDS definitions to exclude history of deep vein thrombosis for PVD = 1; as well as current use of anticoagulation medication, having recurrent cellulitis and skin infections for PVD = 2 since these clinical findings were deemed not reflective of PVD.
Mortality and hospitalizations
The determination of cause-specific mortality in the HEMO Study has been previously described [16] . The cause-specific infectious and cardiac deaths were selected for this report since these are the most common etiologies of death among HD patients. The four cardiac causes of death were (i) ischemic heart disease (IHD), (ii) congestive heart failure, (iii) arrhythmias and conduction problems and (iv) other heart diseases. Hospitalizations were examined only as a composite of 'first cardiac hospitalization or all-cause mortality' and 'first cardiac hospitalization or cardiac death' due to the competing risks of cardiac hospitalization and increased mortality. We were not able to examine multiple events over time due to lack of data in the HEMO Study database for repeated events. There was blinded adjudication of all study outcomes.
HRQOL and other variables
At randomization and annually during follow-up, HEMO Study patients responded to HRQOL surveys as previously described [17-19, 16, 20-22] . The 'Kidney Disease Quality of Life-Long Form (KDQOL-LF)' assesses generic HRQOL using the '36-item short-form (SF-36) questionnaire' and kidney disease-targeted HRQOL domains including Sleep Quality scores for patients in the HEMO Study [18, [22] [23] [24] [25] [26] . The SF-36 questionnaire yields eight multi-item scales that measure physical functioning, bodily pain, mental health, general health, vitality, role emotional, role physical and social functioning. The range of scores for the SF-36 subscales is 0-100, with a higher score reflecting better health and well-being. The SF-36 also produces two summary measures of physical and mental health [27, 28] , the Physical Component Summary score (PCS) and the Mental Component Summary score. The KDQOL-LF assessment of sleep quality provides an overall score with a higher value reflecting better sleep quality [21] .
Statistical analysis
Baseline variables were summarized using mean ± SD for continuous variables and percentages for categorical variables. Differences in summary statistics were tested using (i) generalized linear models for continuous variables, (ii) chi-square tests for nominal variables and (iii) Jonckheere-Terpstra for ordinal tests of trend. Kruskall-Wallis tests were used if data had a non-normal distribution. To understand the relationship between PVD and mortality, single covariate Cox models, with subsequent tests of proportionality, were fit to the data. To calculate adjusted hazard rates for mortality, model selection methods were utilized as follows. To determine a single set of covariates for modeling, single variable Cox proportional hazards models were fit, after creating a data set with no missing data, for potential candidate variables. Any covariate significant at P < 0.2 in any of the mortality models was kept for inclusion in all subsequent multivariate mortality models. It was decided, a priori, that common confounders such as age, gender, race, dialysis flux and dose group and diabetic status were to be forced into the models as known confounders of PVD with mortality.
Any variables violating the proportionality assumption were entered into the multivariable models as interactions with time and declared significant in a backward selection model strictly at P < 0.05. Other interactions with PVD of interest such as phosphorus-calcium and diabetes-smoking were investigated for all-cause mortality only, also in a backward selection model strictly at P < 0.05.
Hazard rates were then tabulated along with upper and lower 95% confidence intervals. The variables included in the adjusted analyses included age, sex, race, dose and flux group, diabetes, duration of HD, access, ICED score with PVD excluded, diastolic blood pressure, smoking status, phosphorus, total cholesterol and serum albumin.
Baseline HRQOL variables were modeled via generalized linear models to reflect a linear ordinal trend, after ruling out higher order polynomial effects, and the mean scores were tabulated along with their SDs and P-values.
Selection of covariates
In order to account for confounding on mortality, we adjusted our survival analyses for baseline patient characteristics that have been found to be associated with mortality of ESRD patients in previous studies [14, 16, 29, 30] . (i) Demographic and clinical: age, gender, race, body mass index (BMI), weight, blood pressure and smoking status ('never smoked' versus 'past' or 'current smoking'). (ii) Dialysis-related factors: duration of dialysis, residual renal function (absent or present based on a residual urine output of <200 mL/day) and dialysis access [dialysis catheter versus all other (arteriovenous fistula, arteriovenous graft or other)]. (iii) Laboratory tests: calcium (milligrams per deciliter), phosphorus (milligrams per deciliter), serum total cholesterol (milligrams per deciliter) and serum albumin (grams per deciliter). 'Albumin' in HEMO was measured by immunonephelometry [31] . (iv) Comorbidity: ICED score (scored with and without the PVD) and diabetes mellitus. (v) Treatment arms: since these data were collected in the setting of a randomized trial, we included the treatment arms as covariates.
Results
Baseline characteristics
Baseline characteristics of patients with PVD are summarized in Table 1 . Among the 1846 patients included in the study, 1425 (77.2%) had neither a history nor a current diagnosis of PVD, 183 (9.9%) had mild PVD, 178 (9.6%) had moderate PVD and 60 (3.3%) had severe PVD. Compared to the entire HEMO Study cohort, patients with more severe PVD were older and less likely to be African-American. In addition, several potentially modifiable risk factors were associated with more severe PVD. Patients with increased PVD severity were more likely to have smoked, more likely to have IHD and diabetes, have lower diastolic blood pressure, have a higher ICED score and have lower serum albumin values. Duration of dialysis also significantly increased with PVD severity; those with mild and moderate PVD underwent the fewest number of years on dialysis, while those with severe PVD underwent a comparable amount of time on dialysis as those without any PVD. In comparison to those without PVD, patients with PVD were less likely to report current or past drug use. Table 2 shows potential risk factors that were significantly associated with increased PVD severity after adjusting for age, sex, race, Kt/V and flux group in a multivariable ordinal logistic stepwise selection model. Women, African-Americans, and those with higher albumin levels were less likely to have a higher severity of PVD score. However, those with IHD and higher ICED scores were likely to have higher PVD scores.
Mortality and morbidity
The relationship of PVD severity to all-cause and causespecific mortality and cardiac hospitalizations is listed in Table 3 . Those with more severe PVD were more likely to suffer higher all-cause mortality, cardiac death, particularly from IHD in those with moderate or severe VD and infectious death in those with mild or severe PVD. Increasing severity of PVD was also associated with the composite end points of first cardiac hospitalization or allcause mortality (P < 0.001) and first cardiac hospitalization or cardiac death (P < 0.001). There was no significant association found between PVD severity and cardiac death due to heart failure (P = 0.06), arrhythmia (P = 0.93) or other heart diseases (P = 0.23).
The patients with the most severe PVD exhibited the highest all-cause mortality (P = 0.001, 1A), cardiac mortality (P = 0.001, 1B) in those with moderate or severe PVD and infectious mortality (P < 0.001, 1C), though the associations were attenuated compared to unadjusted analyses (Tables 3 and 4) . Unlike the unadjusted analyses, infectious mortality increased in a graded fashion with increasing PVD severity in the adjusted analyses. Of note, when stratified by diabetic subgroups (with or without diabetes), the graded increase in mortality with increasing PVD severity was unchanged.
Health-related quality of life PVD severity was significantly associated with HRQOL scores in several domains as summarized in Table 5 . Increased PVD severity was also significantly associated with lower physical function (P < 0.001), lower role physical (P < 0.001), lower bodily pain (P = 0.01), lower general health (P < 0.001), lower vitality (P = 0.001), lower social functioning (P < 0.001) and lower Physical Component Summary score (P < 0.0001). There was no relation between PVD and role emotional (P = 0.60), mental health (P = 0.22), the Mental Component Summary score (P = 0.50) or sleep quality (P = 0.40).
Discussion
Our study suggests a high prevalence of PVD among HD patients in the USA. The overall prevalence of 26.4% is consistent with findings from both the CHOICE study and DOPPS [6, 7] . Increased severity of PVD was associated with increased rates of hospitalization, decrements in HRQOL and an increased risk of death. This work is novel in that it demonstrated that PVD was associated with both cardiovascular and infectious disease mortality. These findings underscore the burden of PVD and demonstrate that PVD severity assessed at baseline from medical records is predictive of mortality and morbidity. Collapsed to mild versus none due to low/zero cell counts. The ICED Score 0-1 group serves as the reference.
Our study shows associations between PVD and potential risk factors that are both non-modifiable (e.g. increased age, non-African-American race and higher ICED score) and those that may coexist with, be a consequence of or be a cause of PVD (e.g. smoking history, IHD, diabetes, low diastolic blood pressure, lower serum albumin, increased time on dialysis and current or past drug use). Since these conditions are ascertained simultaneously, the exact relationship cannot be determined. Our findings are mostly consistent with previous studies, which examined risk factors associated with PVD diagnosis by analyzing data from the HEMO Study (first 1000 patients enrolled), the United States Renal Data System Dialysis Morbidity and Mortality Study (DMMS), the CHOICE study and the DOPPS, respectively [1, 4, 6, 7] . Consistent with previous studies (DOPPS and DMMS), we found that certain uremia-related variables, including serum calcium and phosphorus, were not significantly associated with PVD [1, 6] . Consistent with previous analysis of the HEMO Study, African-American race was associated with a reduction in PVD [4] . There are several potential explanations for this divergence, including underlying genetic, environmental and health care access conditions, particularly since we relied on the medical record to determine PVD diagnoses. Possibly, African-Americans are less likely to develop PVD. Alternatively, PVD may continue undiagnosed until manifesting as severe PVD or disparities in their access to treatment after diagnosis may cause more progression to severe PVD. It is possible that this difference in PVD severity may contribute to the differential outcomes of African-American patients on HD.
Our findings indicate that PVD severity is significantly associated with decrements in HRQOL, particularly within the physical function domain. Others have shown that PVD greatly impacts HRQOL, and change in HRQOL has become a well-validated measurement for the effectiveness of PVD-related therapy [32] . Lastly, because patients who have undergone amputation were categorized as having either moderate or severe PVD, our study implies that greater PVD severity is associated with worse functional status and worse HRQOL at least in part due to amputation. The marked decrement in physical functioning of ESRD patients may be due in part to chronic health conditions such as PVD. Higher PVD severity was also associated with higher bodily pain, which is reflected in lower scores for bodily pain in the SF-36 scoring system. Thus, the diagnosis and management of PVD should be a target for the care of patients with ESRD.
Finally, we have previously examined the relationship between the HRQOL and both the dose and flux of hemodialysis. No associations were found between flux and HRQOL measurements. High-dose HD treatment was associated with less pain and greater PCS [16] . Given the substantial burden of comorbid disease, e.g. PVD, the small improvement in HRQOL due to changes in HD dose and flux may have been masked.
To realize prompt and early treatment of PVD, the current limitations in diagnosing PVD must be addressed. The current standard non-invasive method for diagnosing PVD among patients who are to begin dialysis is the use of ankle brachial index (ABI) [11] . However, patients with diabetes mellitus or renal failure may have falsely elevated ABI due to calcification of the arteries [33] . In addition, ultrasonography (US) may be another important adjunct to ABI in detecting PVD in ESRD patients on HD. Kitaura et al. [34] compared US and ABI as methods of assessing lower-limb PVD in patients at the onset of HD and found US to be a more sensitive method of detecting PVD. In a recent study, Ogata et al. [35] corroborated the utility of duplex US for detection of peripheral artery disease (PAD) in 315 outpatients on HD. They showed that PAD defined by duplex US was more prevalent among HD patients compared with the general population and that ABI may be unsuitable for detecting PAD in HD patients, particularly in those who are diabetic, older or malnourished. Our study suggests that use of a PVD severity scoring index like the IDS may be a useful surrogate for PVD diagnosis even without ABI, given our finding that PVD severity score is associated with important clinical outcomes. Finally, screening for PVD among all patients with chronic kidney disease (CKD) remains controversial. In light of the significant associations between PVD severity and mortality among dialysis patients, patients with CKD may benefit from early detection and treatment for PVD [11] .
Strengths and limitations
A strength of our study is that the data examined came from a prospective multi-center clinical trial. Hence, the information on PVD severity, comorbidities and causes of mortality are likely to be accurate and reliable. The findings of our report should be judged in light of several limitations. First, the classification of some patients with subclinical PVD was analyzed as patients without PVD. This would have created a misclassification bias which would have biased toward null findings. Second, PVD severity was obtained at the beginning of the HEMO Study. While effective treatments for PVD among patients on HD remain elusive, some patients with the same baseline PVD severity might have received different interventions, which would have affected not only their quality of life and survival but also the severity of their PVD over the course of the HEMO Study. Third, subjects in the HEMO Study were enrolled in 1995-2000. Recent analysis of National Inpatient Sample from 1996 to 2005 shows trends of an increase in endovascular procedures and a decrease in the likelihood of amputations among patients with PAD in the USA [36] . Compared to patients enrolled in the HEMO Study, current patients may have improved morbidity and mortality from physicians having more knowledge and experience with treatment of PVD, though more updated data is needed to measure changes in mortality and morbidity among these more recent patients. Fourth, there were no data on inflammatory markers in the HEMO Study, which may have influenced outcomes. Furthermore, the generalizability of the population studied in the HEMO Study may be limited due to the inclusion of only prevalent patients on HD rather than both prevalent and incident patients. This HD population would potentially select for long-term survivors, who may have different characteristics and comorbidities from incident HD patients. Thus, the findings in our study may not be generalizable to all HD populations, due to survival bias. Another key entry criterion that could limit generalizability was the inclusion of only those patients who would be expected to be able to reach a Kt/V of >1.3 in <5 h of HD, thus selecting for patients with a lower BMI (<100 kg). Finally, there were more African-American patients in the HEMO Study than in other general HD populations, which also limits generalizability.
Conclusion
This is the first study to analyze PVD and PVD severity in the entire HEMO Study data, and the ordinal statistical regression enabled us to demonstrate that PVD severity exerts significant impact on mortality and HRQOL. Our study demonstrated that patients with more severe PVD had a significantly worse prognosis and lower HRQOL. Moreover, we have identified several factors that may provide better methods for assessing the prognosis and treatment of specific subsets of ESRD patients. Our findings also emphasize the importance of early detection of PVD, in order to initiate prompt therapy to prevent progression of PVD before amputation becomes necessary. Such an approach would help decrease morbidity and mortality and improve HRQOL in the ESRD population with PVD.
